favorable-risk rcc: options for vegf tki monotherapy
Published 4 years ago • 94 plays • Length 4:09Download video MP4
Download video MP3
Similar videos
-
5:15
favorable-risk rcc: frontline vegf tki/io combinations
-
3:11
treatment options for intermediate/poor-risk rcc
-
2:56
dr singer on the efficacy of io/tki doublets in advanced rcc
-
5:04
favorable-risk rcc: factors in selecting therapy
-
4:27
vegf-tki therapy in first-line mrcc
-
8:15
choosing an io/tki doublet for rcc patients: efficacy data, dosing, and more
-
5:11
selecting immunotherapy versus vegf tki for mrcc
-
6:06
which patients with rcc are right for monotherapy?
-
6:53
kidney cancer - current treatment options for metastatic renal cancer part 1
-
19:10
renal cell carcinoma (rcc) - kidney tumors - neoplasms - renal pathology - nephrology
-
5:11
പിറന്നതിന് ശേഷവും കുട്ടിയുടെ കിഡ്നിക്ക് പ്രശ്നം കാണിക്കുന്നത് ഭാവിയിൽ ഗുരുതരമാകുമോ? | dr.q
-
7:18
vegf tki therapy in the adjuvant setting of rcc
-
4:23
second-line options for poor-risk advanced rcc
-
1:04
dr. jonasch on first- and second-line options for patients with rcc
-
51:09
immunotherapy-based combinations for advanced/metastatic renal cell carcinoma: asco gu 2023
-
4:14
second-line treatment options for advanced rcc
-
7:03
ipilimumab/nivolumab for favorable-risk mrcc
-
10:37
patient scenarios and treatment considerations in the adjuvant rcc setting
-
4:23
first-line therapy options for rcc: lessons from checkmate 214 and keynote-427
-
3:54
treating intermediate and favorable-risk renal cell carcinoma
-
6:36
choosing post-progression therapy for metastatic rcc
-
1:06
promising tki-ici combinations for non-clear cell rcc